How would you approach adjuvant chemotherapy for high grade pleomorphic/dedifferentiated liposarcoma?
Does anatomic location (eg retroperitoneal or thoracic) affect your treatment decision?
Answer from: Medical Oncologist at Academic Institution
To answer this question we have to first discuss the benefits of adjuvant chemotherapy. The almost exclusive focus has been on doxorubicin based therapy, either as a single agent, in combination with ifosfamide, or in 1 case combined with ifosfamide and dtic. Each study individually has small number...
Answer from: Medical Oncologist at Community Practice
These are not impressive results for a retrospective study where I am sure fitter patients are probably selected for therapy. these are very toxic drugs.
Can you break down the numbers of pleomorphic in this abstract ( unpublished) to see if we can get a better idea
What level of evidence sho...
Comments
Medical Oncologist at Rutgers Cancer Institute of New Jersey 400 patients total. 53% DDLPS; 35% MLPS; 12% PLPS....
Answer from: Medical Oncologist at Community Practice
therefore 48 patients only were pleomorphic.
in fact, the survivors could easily be the not so bad actors and we may be hurting patients. in their last days of life.
I think we have to learn to say no without data, particularly when for years chemotherapy has been so marginal in soft ti...
Comments
Medical Oncologist at Rutgers Cancer Institute of New Jersey I think the point was that these are pleomorphic b...
Medical Oncologist at Siri Onclogy and hematology Infusion Service Robert, I read this abstract now and in a multivar...
Medical Oncologist at Rutgers Cancer Institute of New Jersey I don't think they used cytoxan, rather they poorl...